Novuson Surgical Inc. offering is now closed and is no longer accepting investments.

Soundly Simplifying Surgery


Novuson has developed what we believe is the next generation of electrosurgical devices that are safer and more effective than current electrosurgical devices. We plan for our Direct Therapeutic Ultrasound surgical devices to disrupt the surgical device market, improving patient safety. Novuson is pre-revenue and in the prototype phase - - (Novuson has four prototype products (of which our 3mm Mini LS is close to regulatory clearance) and an energy console.)
... Show more
This Reg CF offering is made available through StartEngine Capital, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.
Novuson Surgical Inc.


Reasons Icon

Safer Technology - Our patented DTU technology leaves no burned tissue, no charred tissue, and no carcinogenic smoke

Reasons Icon

Market Disruptor - Novuson’s technology solves the weaknesses of the two market-dominant electrosurgical solutions

Reasons Icon

Strategic Investments and Partnerships - Secured investment from major medical technology company and currently in negotiation for additional strategic partnerships


The first substantive innovation in vessel sealing & dividing in over 25 years

We believe Novuson’s patented technology is unprecedented for surgical and trauma procedures. It’s a trailblazing innovation in vessel sealing and dividing and hemostasis (bleeding control). The company is developing its direct therapeutic ultrasound (DTU) technology for coagulation and hemostatic control. 

We believe our DTU technology speeds up surgeries and arms clinicians with rapid controls of bleeding associated with traumatic injuries. Novuson's solution does not transmit electricity through the patient, unlike market-dominant solutions, more importantly, no burned or charred tissue or any carcinogenic smoke is created in the process, resulting in safer procedures. This technology is built into a device with three configurations: the 3mm UltraStat Mini LS, 5mm UltraStat LS, and 10mm Maxx. Four total products are in the prototype phase, with one having its design for manufacturing (DFM) completed and its first production devices built out. 

*Images are computer generated demo versions. Product is still currently under development

Novuson has completed the first build of its production validation test (PVT) articles. The next steps are to perform sterilization, safety, packaging, shipping, shelf-life studies, and other validation studies required by the FDA. We will file for 510k clearance with the FDA once these studies are complete. 

The company was born out of the University of Washington’s highly regarded Applied Physics Laboratory’s Center for Industrial and Medical Ultrasound. Our founder and CEO is an alumnus and has designed biomedical instrumentation and devices for approximately 20 years. 

the problem

Existing electrosurgical technologies lack safety & precision, leading to harmful consequences

According to our research, 33% of all surgeries experience complications. Does that number sound high to you? 

That’s probably because 49% of those surgical complications were avoidable–– 77% of which were due to technical errors. If these tools were more safe, precise, and versatile, these devastating numbers could shrink. There is a need for innovative surgical solutions that improve patient outcomes and ultimately reduce hospital costs.

Source: Healy et al and Stokes et al

The two market-dominant electrosurgical solutions for sealing and dividing tissue are radio frequency (RF) and harmonic. Both solutions cause smoke, charring, and thermal damage to tissue with each application. Patients are already worried about the ailment that requires surgery. The last thing they should be worried about is the technology used to treat them.

Existing RF solutions run high-frequency electrical currents through the patient, and utilize that transmission. Harmonic solutions employ mechanically vibrating cutting bars, and utilize that friction heat. Both solutions achieve a level of success that is severely limited in speed, precision and range of application.

The cultivation of energy for those solutions also puts hospital buildings at risk. One out of every 200 uses of an electrosurgical device results in an adverse event, such as operating room fires or severe burns due to electrical arcing. 

Surgical fires are not only a danger to patients but also to medical staff as a result of several factors including toxic gases and vapors that get released, as well as exposure to viruses and bacteria.

Source: Massarweh, N. N., Cosgriff, N., & Slakey, D. P. (2006)

Example of a surgical fire

The market

$6.4 billion total addressable market, electrosurgical devices used in 89% of all surgical procedures

The surgical device market is valued at an estimated $50 billion. Electrosurgical devices (energy devices) like ours are approximately 12% of the $50 billion medical device market. This translates to a total addressable market of $6.4 billion in 2020. The 5.2% CAGR can drive up our total addressable market to $8.8 billion by 2025.

Source: Global MD&D Market Report EMS Summit, Statistics MRC ID: 283193, Grand View Research Oct 2016, Markets and Markets (2916860), BCC Research (HLCO93A)

For every surgery completed, there’s an 89% chance the surgeon used an electrosurgical device. The technology behind the essential device was likely radio frequency (RF) or harmonic. Radio frequency devices transmit electricity from one end-effector to the other. The electricity cauterizes and the tissue is then cut with a built-in razor knife. Harmonic devices generate an ultrasonic waveguide to create a mechanical motion at the clamping end-effector. Friction is created, which cauterizes and burns through the tissue. 

the solution

Innovations in precision, safety, & versatility for electrosurgical solutions

Patients and surgeons deserve innovation to achieve successful operations. Our solution does not run electricity through the patient, burn or char their tissue, or generate any carcinogenic smoke in the operating room. Novuson’s electrically neutral design makes it safer and cleaner than conventional technologies.

*Images are computer generated demo versions. Product is still currently under development

Our technology debuts in an improved surgical device for sealing and dissecting tissue, as well as whole organ cauterization. Our devices come in three configurations for a wide range of clinical applications. Medical professionals can choose between the 3mm UltraStat Mini LS or the 5mm UltraStat LS models for sealing/dissecting and the 10mm Maxx model for whole organ cauterization.

Each device has jaws that clamp down on tissue. Confined energy is created between these jaws, delivering a controlled, uniform therapy zone. We do this without passing an electric current through the patient–– an unprecedented level of performance. 

*Images are computer generated demo versions. Product is still currently under development

Novuson has a “Razor-Razor Blade” business model. Our applicator unit sales are based on the number of surgical procedures performed, and there are 410 million annual surgical procedures worldwide. Our generator sales are based on the number of surgical suites the equipment is placed in, and there are 405K surgical suites world-wide. We will enter the market through direct sales at ambulatory surgical centers (ASCs). Our key opinion leaders there will conduct surgical studies with various procedures and publish the results. Traction with ASCs will jumpstart Novuson to develop strategic partnerships for distribution in hospital systems.


We raised $5 million & won the NIH STTR Award 

Our accomplishments result from our innovative technology and the industry relationships we cultivate. We raised $5.57 million through series A financing and two convertible notes. Our Novuson platform device won the National Institute of Health’s (NIH) STTR Award for the perioperative device. We were awarded the HemoClamp SBIR grant ($1.5 million) and the Periop SBIR grant ($1.47 million). Four prototypes have been developed, with one in the process of design for manufacturing. Final reports were submitted to NIH with all grant milestones achieved. 

*Images are computer generated demo versions. Product is still currently under development

In early 2019, we began collaborating with med-tech companies. Three months later, we achieved the first tranche milestone: sealing in under 3 seconds. The following year, we achieved the second tranche milestone: dividing in under 5 seconds.

Additional partnership milestones:

  • Licensing agreement formed with the University of Washington in 2015

  • Cooperative research and development agreement formed with Madigan Army Medical Center in 2016

  • Participated in a pre-meeting with the FDA in 2017

  • Distribution agreement in Italy in 2018

  • Received term sheet for strategic partnerships in China in September 2021

Product development milestones:

  • Filed international patents in 6 countries in 2020

  • Demonstrated 1st production validation test articles that meet Novuson's value proposition in March 2021

  • Two new patents were awarded in January 2021

  • Newest patent was awarded in October 2021

why invest

Major partnerships & agreements can help us become the premier electrosurgical device manufacturer 

It takes a collaborative team of surgeons and medical professionals to ensure outstanding patient outcomes. That’s why we are employing partnerships and agreements to become the leading electrosurgical device manufacturer. 

Success comes from synergy. Novuson is currently in discussions with five major medical device manufacturers to secure strategic partnerships and licensing agreements. These relationships will provide extraordinary growth opportunities. We want “Novuson” to pop into the head of every medical professional who needs new electrosurgical devices. 

Novuson plans to grow with nimble product development efforts. We hope to launch a new product every six to nine months and currently have three additional prototypes ready for design for manufacturing. Interest from major electrosurgical device manufacturers to integrate Novuson’s technology could further diversify our market presence.

The current technologies that seal and divide tissue do not prioritize the safety of patients and the success of surgeons. It’s time to finally cut through the limitations and risks with innovation. 

*Images are computer generated demo versions. Product is still currently under development

We envision this part of your journey with Novuson as an exciting ribbon-cutting ceremony. It celebrates the future of surgical improvement. Your investment is like that shiny pair of scissors that cuts the ribbon and exhilarates the crowd. Would you like to do the honors?


11824 North Creek Parkway North,Suite103
Bothell, WA 98011

Novuson has developed what we believe is the next generation of electrosurgical devices that are safer and more effective than current electrosurgical devices. We plan for our Direct Therapeutic Ultrasound surgical devices to disrupt the surgical device market, improving patient safety. Novuson is pre-revenue and in the prototype phase - - (Novuson has four prototype products (of which our 3mm Mini LS is close to regulatory clearance) and an energy console.)


Stuart B Mitchell
Stuart B Mitchell

Experienced executive with a demonstrated history of working in the research industry and academia. Skilled in Bioreactor Development, Medical Devices, Biomedical Devices, Biomechanics, and Tissue Engineering. Strong entrepreneurship professional with a Doctor of Philosophy (Ph.D.) focused in Bioengineering from University of Washington.

Carla Corkern

Carla Corkern


Intellectually curious and passionate about people, process, and profit!

I love to manage processes, create cross-functional teams, create high energy & high performing teams.

I've succeeded in start-up environments, turn around scenarios and M&A integrations for both public and private companies by building plans, teams, campaigns, processes, from beginning to on-going concern. Pre-revenue to ~$50 Million in ARR.

Experience in many technology markets: Healthcare, Automation, SAAS Platforms for Supply Chain and Healthcare, Enterprise infrastructure & applications, EAI, corporate portals, knowledge management, content management, search technology, XML infrastructure technology, security/user management, wireless/mobile apps, networking, groupware, personal productivity applications

Sam Liao

Sam Liao


Previously with Lakeside, Metropolitan Investments and Merrill Lynch Capital Investments. Mr. Liao brings financial and investment oversight to Novuson’s Board

Marco Daoura

Marco Daoura

EVP of Product and Programs

Mr. Daoura graduated from the University of Washington with both a Bachelor of Science in Electrical Engineering and a Master of Science in BioEngineering with focus on Control Theory and Molecular Biotechnology. He has over 20 years in the healthcare industry from Philips Healthcare to Fujifilm Medical Systems, UltraLinq Healthcare. His work in innovation crosses many multidisciplinary areas from technology development, to technology architecture, program management, product services, product management and marketing, and market commercialization.

Derek Khorsand

Derek Khorsand

Chief Medical Officer

Derek grew up in a small town in southwest Washington and is a graduate of the University of Washington School of Medicine, where he was the top graduate in his class. After a year of training in general surgery, Derek trained in Interventional Radiology at the University of Washington, where he was Chief Resident. He has a strong background in basic and clinical research and experience in medical device commercialization.


Novuson Surgical Inc.
Jun 30, 2022
Common Stock

Maximum Number of Shares Offered subject to adjustment for bonus shares



Novuson Surgical Inc.

Corporate Address


11824 North Creek Parkway North,Suite103, Bothell, WA 98011

Offering Minimum



Offering Maximum



Minimum Investment Amount

(per investor)




Offering Type



Security Name


Common Stock

Minimum Number of Shares Offered



Maximum Number of Shares Offered



Price per Share



Pre-Money Valuation



*Maximum Number of Shares Offered subject to adjustment for bonus shares. See Bonus info below.

Voting Rights of Securities Sold in this Offering

Voting Proxy. Each Subscriber shall appoint the Chief Executive Officer of the Company (the “CEO”), or his or her successor, as the Subscriber’s true and lawful proxy and attorney, with the power to act alone and with full power of substitution, to, consistent with this instrument and on behalf of the Subscriber, (i) vote all Securities, (ii) give and receive notices and communications, (iii) execute any instrument or document that the CEO determines is necessary or appropriate in the exercise of its authority under this instrument, and (iv) take all actions necessary or appropriate in the judgment of the CEO for the accomplishment of the foregoing. The proxy and power granted by the Subscriber pursuant to this Section are coupled with an interest. Such proxy and power will be irrevocable. The proxy and power, so long as the Subscriber is an individual, will survive the death, incompetency and disability of the Subscriber and, so long as the Subscriber is an entity, will survive the merger or reorganization of the Subscriber or any other entity holding the Securities. However, the Proxy will terminate upon the closing of a firm-commitment underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933 covering the offer and sale of Common Stock or the effectiveness of a registration statement under the Securities Exchange Act of 1934 covering the Common Stock.

Investment Incentives and Bonuses*



Invest within the first 48 hours and receive 20% bonus shares.

Super Early Bird Bonus

Invest within the first week and receive 15% bonus shares.

Early Bird Bonus

Invest within the first two weeks and receive 10% bonus shares.


Tier 1 | $5,000+

Invest $5,000+ and receive 5% bonus shares.

Tier 2 | $10,000+

Invest $10,000+ and receive 10% bonus shares.

Tier 3| $25,000+

Invest $25,000+ and receive 25% bonus shares.

*All perks occur when the offering is completed.

Investors will only receive a single bonus, which will be the highest bonus rate they are eligible for, with the exception of “audience-based” bonuses.

If a company offers an “audience-based” bonus, this bonus only will stack with any other bonus you are eligible for. An “audience-based” bonus is a bonus that is available to a qualified group of investors based on campaign-specific criteria - such as previous investors, existing customers, or Testing-the-Waters (TTW) reservation holders. An issuer can only offer a single audience-based bonus.

For example, a 10% audience-based bonus (i.e. prior investors) + a 10% OWNer’s bonus would receive an aggregate of 20% bonus shares.

Insider Investment Notice: Officers, directors, executives, and existing owners with a controlling stake in the company (or their immediate family members) may make investments in this offering. Any such investments will be included in the raised amount reflected on the campaign page.

The 10% StartEngine Owners' Bonus

Novuson Surgical Inc. will offer 10% additional bonus shares for all investments that are committed by investors that are eligible for the StartEngine Crowdfunding Inc. OWNer's bonus.

This means eligible StartEngine shareholders will receive a 10% bonus for any shares they purchase in this offering. For example, if you buy 100 shares of Common Stock at $0.64 / share, you will receive 110 shares of Common Stock, meaning you'll own 110 shares for $64. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.

This 10% Bonus is only valid during the investors' eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are canceled or fail.

Investors will only receive a single bonus, which will be the highest bonus rate they are eligible for.

Irregular Use of Proceeds

The Company might incur Irregular Use of Proceeds that may include but are not limited to the following over $10,000: Vendor payments. Any expense labeled “Travel and Entertainment”. Inter company debt or back payments. Salary payments made to one’s self, a friend or relative.



Thank You from Novuson's CEO, Dr. Stu Mitchell

I'd like to say thank you to all of Novuson's new and existing investors as well as everyone that is following Novuson on StartEngine.  Your investment will help Novuson gain traction and improve the safety and precision of surgery.  Our crowdfunding on StartEngine is ending in less than 12 hours.  If you haven't invested yet, Please consider joining our team and helping Novuson improve the safety and precision of surgery.


Stu Mitchell


Novuson Product Validation System - Campaign Closes in 5 Days!

Below is Novuson's Product Validation Test system that is being used for the validation and verification regulatory studies.   Once we raise the funding, systems such as this will be used to conduct sterilization, packaging, shipping, safety, and numerous additional tests required by the FDA.  

Please join Novuson and I in making surgeries safer and more precise!


Novuson Founder.


Novuson Campaign Ending in Less than a Week!

First, I'd like to than all of our new and existing investors for your investments in Novuson.  If you haven't had a change to invest yet, our campaign is ending in a week.  We've hit 10% of our funding goal which will help Novuson achieve some traction.  Whether you’ve already invested or not, you should know that Novuson is committed to building long-term relationships with our investors. Our ultimate goal is to build a community of investors that influence others and act as our brand advocates. We’re confident that we’ll all be working together for a  long time. 



CEO & Founder of Novuson


See How Novuson's Technology Works - See The Sound!

Our campaign is ending soon.  For $256.00 you can invest in our campaign


Novuson Selected as an Innovation Leader

We're proud to be selected as an innovation Leader at the Emerging Medtech Summit in the United Kingdom. Thanks LSI!

Only a few days left on the campaign!


Novuson Accomplishment & Highlights so far in 2022


Novuson selected to present at Emerging Medtech Summit!

Novuson continues to be recognized as an innovate company that will disrupt the surgical device market with our DTU.  Join us in making surgeries safer and more precise!  Only a few days left!


Outtake from LSI 2022 Presentation. Dr. Mitchell talks about surgical smoke!

What is surgical smoke? why is it there? why is it harmful?


Multiple investments in an offering cannot be combined to qualify for a larger campaign perk. Get rewarded for investing more into Novuson Surgical Inc..


StartEngine Owner’s Bonus

This offering is eligible for the StartEngine Owner’s 10% Bonus program. For details on this program, please see the Offering Summary section below.


Tier 1

Invest $5,000+ and receive 5% bonus shares.


Tier 2

Invest $10,000+ and receive 10% bonus shares.


Tier 3

Invest $25,000+ and receive 25% bonus shares.




Cancel anytime before 48 hours before a rolling close or the offering end date.


REWARDSWe want you to succeed and get the most out of your money by offering rewards and memberships!
SECUREYour info is your info. We take pride in keeping it that way!
DIVERSE INVESTMENTSInvest in over 200 start-ups and collectibles!

With Regulation A+, a non-accredited investor can only invest a maximum of 10% of their annual income or 10% of their net worth per year, whichever is greater. There are no restrictions for accredited investors.

With Regulation Crowdfunding, non-accredited investors with an annual income or net worth less than $124,000, are limited to invest a maximum of 5% of the greater of those two amounts. For those with an annual income and net worth greater than $124,000, he/she is limited to investing 10% of the greater of the two amounts.

At the close of an offering, all investors whose funds have “cleared” by this time will be included in the disbursement. At this time, each investor will receive an email from StartEngine with their Countersigned Subscription Agreement, which will serve as their proof of purchase moving forward.

Please keep in mind that a company can conduct a series of “closes” or withdrawals of funds throughout the duration of the campaign. If you are included in that withdrawal period, you will be emailed your countersigned subscription agreement and proof of purchase immediately following that withdrawal.

StartEngine assists companies in raising capital, and once the offering is closed, we are no longer involved with whether the company chooses to list shares on a secondary market, or what occurs thereafter. Therefore, StartEngine has no control or insight into your investment after the close of the live offering. In addition, we are not permitted to provide financial advice. You may want to contact a financial professional to discuss possible investment outcomes.

For Regulation Crowdfunding, investors are able to cancel their investment at any point throughout the campaign up until 48 hours before the closing of the offering. Note: If the company does a rolling close, they will post an update to their current investors, giving them the opportunity to cancel during this timeframe. If you do not cancel within this 5-day timeframe, your funds will be invested in the company, and you will no longer be able to cancel the investment. If your funds show as ‘Invested’ on your account dashboard, your investment can no longer be canceled.

For Regulation A+, StartEngine allows for a four-hour cancelation period. Once the four-hour window has passed, it is up to each company to set their own cancelation policy. You may find the company’s cancelation policy in the company’s offering circular.

Once your investment is canceled, there is a 10-day clearing period (from the date your investment was submitted). After your funds have cleared the bank, you will receive your refund within 10 business days.

Refunds that are made through ACH payments can take up to 10 business days to clear. Unfortunately, we are at the mercy of the bank, but we will do everything we can to get you your refund as soon as possible. However, every investment needs to go through the clearing process in order to get sent back to the account associated with the investment.

Both Title III (Regulation Crowdfunding) and Title IV (Reg A+) help entrepreneurs crowdfund capital investments from unaccredited and accredited investors. The differences between these regulations are related to the investor limitations, the differing amounts of money companies are permitted to raise, and differing disclosure and filing requirements. To learn more about Regulation Crowdfunding, click here, and for Regulation A+, click here.

@ 2022 All Rights Reserved

Apple Store Logo

Get To Know Us

Our Team


Important Message


Unless indicated otherwise with respect to a particular issuer, all securities-related activity is conducted by regulated affiliates of StartEngine: StartEngine Capital, LLC, a funding portal registered here with the US Securities and Exchange Commission (SEC) and here as a member of the Financial Industry Regulatory Authority (FINRA), or StartEngine Primary, LLC, a broker-dealer registered with the SEC and FINRA/SIPC . You can review the background of our broker-dealer and our investment professionals on FINRA’s BrokerCheck here. StartEngine Secondary is an alternative trading system regulated by the SEC and operated by StartEngine Primary, LLC, a broker dealer registered with the SEC and FINRA. StartEngine Primary, LLC is a member of SIPC and explanatory brochures are available upon request by contacting SIPC at (202) 371-8300.

Investment opportunities posted and accessible through the site are of three types:

1) Regulation A offerings (JOBS Act Title IV; known as Regulation A+), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Primary, LLC (unless otherwise indicated). 2) Regulation D offerings (Rule 506(c)), which are offered only to accredited investors. These offerings are made through StartEngine Primary, LLC. 3) Regulation Crowdfunding offerings (JOBS Act Title III), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Capital, LLC. Some of these offerings are open to the general public, however there are important differences and risks.

Any securities offered on this website have not been recommended or approved by any federal or state securities commission or regulatory authority. StartEngine and its affiliates do not provide any investment advice or recommendation and do not provide any legal or tax advice with respect to any securities. All securities listed on this site are being offered by, and all information included on this site is the responsibility of, the applicable issuer of such securities. StartEngine does not verify the adequacy, accuracy or completeness of any information. Neither StartEngine nor any of its officers, directors, agents and employees makes any warranty, express or implied, of any kind whatsoever related to the adequacy, accuracy, or completeness of any information on this site or the use of information on this site. See additional general disclosures here.

By accessing this site and any pages on this site, you agree to be bound by our Terms of use and Privacy Policy, as may be amended from time to time without notice or liability.

Canadian Investors Investment opportunities posted and accessible through the site will not be offered to Canadian resident investors. Potential investors are strongly advised to consult their legal, tax and financial advisors before investing. The securities offered on this site are not offered in jurisdictions where public solicitation for offerings is not permitted; it is solely your responsibility to comply with the laws and regulations of your country of residence.

California Investors Only – Do Not Sell My Personal Information (800-317-2200). StartEngine does not sell personal information. For all customer inquiries, please write to

StartEngine’s Reg A+ offering is made available through StartEngine Crowdfunding, Inc. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. For more information about this offering, please view StartEngine’s offering circular and risk associated with this offering.